SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
21-Dec-07 12:17 PM View: | Parker David L Vice President | Introgen Therapeutics Inc. (INGN) | 20-Dec-07 | Option Exercise | 20,000 | $0.52 | $10,380.00 | 28% 71.81K to 91.81K | |
03-Oct-07 1:50 PM View: | Albrecht James W Jr Chief Financial Officer | Introgen Therapeutics Inc. (INGN) | 01-Oct-07 | Grant | 32,661 | $0.00 | $32.66 | 157% 20.8K to 53.46K | |
01-Jun-07 3:49 PM View: | Hutt Peter Barton Director | Introgen Therapeutics Inc. (INGN) | 30-May-07 | Grant | 7,919 | $0.00 | $7.92 | 106% 7.5K to 15.42K | |
01-Jun-07 3:22 PM View: | Long Charles E Director | Introgen Therapeutics Inc. (INGN) | 30-May-07 | Grant | 7,919 | $0.00 | $7.92 | 45% 17.5K to 25.42K | |
01-Jun-07 4:14 PM View: | Gillis Stephen Malcolm Director | Introgen Therapeutics Inc. (INGN) | 30-May-07 | Grant | 7,919 | $0.00 | $7.92 | 106% 7.5K to 15.42K | |
01-Jun-07 2:52 PM View: | Cunningham William H Dr Director | Introgen Therapeutics Inc. (INGN) | 30-May-07 | Grant | 7,919 | $0.00 | $7.92 | 55% 14.5K to 22.42K | |
01-Jun-07 4:29 PM View: | Kapoor John N Director | Introgen Therapeutics Inc. (INGN) | 30-May-07 | Grant | 7,919 | $0.00 | $7.92 | < 1% 3.35M to 3.35M | |
07-Feb-08 10:00 PM View: | Enloe J David Jr Sr. VP | Introgen Therapeutics Inc. (INGN) | 09-Mar-07 | Gift | 102,400 | -- | -- | (100%) 102.4K to 0 | |
08-Feb-07 4:50 PM View: | Enloe J David Jr Sr. VP | Introgen Therapeutics Inc. (INGN) | 06-Feb-07 | Option Exercise | 102,400 | $0.66 | $67,180.80 | 100% 0 to 102.4K | |
06-Sep-06 1:46 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 06-Sep-06 | Market Sale | 20,439 | $4.04 | $82,573.60 | (< 1%) 11.25M to 11.23M | 54% |
06-Sep-06 3:20 PM View: | Parker David L Senior Vice President | Introgen Therapeutics Inc. (INGN) | 05-Sep-06 | Option Exercise | 15,000 | $0.52 | $7,785.00 | 26% 56.81K to 71.81K | |
06-Sep-06 1:46 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 05-Sep-06 | Market Sale | 13,000 | $3.99 | $51,870.00 | (< 1%) 11.26M to 11.25M | 54% |
06-Sep-06 1:46 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 01-Sep-06 | Market Sale | 20,100 | $3.94 | $79,194.00 | (< 1%) 11.28M to 11.26M | 53% |
05-Sep-06 2:14 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 31-Aug-06 | Market Sale | 33,530 | $3.96 | $132,779.00 | (< 1%) 3.81M to 3.78M | 54% |
01-Sep-06 8:00 AM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 30-Aug-06 | Market Sale | 10,500 | $3.96 | $41,580.00 | (< 1%) 3.82M to 3.81M | 54% |
30-Aug-06 3:25 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 29-Aug-06 | Market Sale | 13,484 | $3.89 | $52,452.80 | (< 1%) 7.67M to 7.66M | 53% |
30-Aug-06 3:25 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 28-Aug-06 | Market Sale | 36,739 | $3.91 | $143,650.00 | (< 1%) 7.71M to 7.67M | 53% |
23-Aug-06 2:55 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 21-Aug-06 | Market Sale | 19,208 | $3.94 | $75,679.50 | (< 1%) 3.89M to 3.87M | 53% |
21-Aug-06 4:30 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 17-Aug-06 | Market Sale | 23,902 | $3.85 | $92,022.70 | (< 1%) 3.91M to 3.89M | 52% |
18-Aug-06 11:44 AM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 16-Aug-06 | Market Sale | 41,355 | $3.85 | $159,217.00 | (1%) 3.96M to 3.91M | 52% |
16-Aug-06 2:06 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 15-Aug-06 | Market Sale | 21,212 | $3.90 | $82,726.80 | (< 1%) 3.98M to 3.96M | 53% |
14-Aug-06 10:00 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 14-Aug-06 | Market Sale | 34,700 | $3.90 | $135,330.00 | (< 1%) 8.02M to 7.99M | 53% |
14-Aug-06 10:00 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 11-Aug-06 | Market Sale | 30,000 | $3.91 | $117,300.00 | (< 1%) 8.05M to 8.02M | 53% |
14-Aug-06 10:00 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 10-Aug-06 | Market Sale | 42,695 | $4.01 | $171,207.00 | (1%) 4.08M to 4.04M | 54% |
25-May-06 10:00 PM View: | Long Charles E Director | Introgen Therapeutics Inc. (INGN) | 23-May-06 | Grant | 7,500 | $0.00 | $7.50 | 75% 10.0K to 17.5K | |
25-May-06 10:00 PM View: | Gillis Stephen Malcolm Director | Introgen Therapeutics Inc. (INGN) | 23-May-06 | Grant | 7,500 | $0.00 | $7.50 | 100% 0 to 7.5K | |
25-May-06 10:00 PM View: | Cunningham William H Dr Director | Introgen Therapeutics Inc. (INGN) | 23-May-06 | Grant | 7,500 | $0.00 | $7.50 | 107% 7.0K to 14.5K | |
25-May-06 10:00 PM View: | Kapoor John N Director | Introgen Therapeutics Inc. (INGN) | 23-May-06 | Grant | 7,500 | $0.00 | $7.50 | < 1% 3.34M to 3.35M | |
25-May-06 10:00 PM View: | Hutt Peter Barton Director | Introgen Therapeutics Inc. (INGN) | 23-May-06 | Grant | 7,500 | $0.00 | $7.50 | 100% 0 to 7.5K | |
06-Apr-06 8:01 AM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 04-Apr-06 | Market Sale | 65,845 | $5.42 | $356,880.00 | (2%) 4.15M to 4.08M | 66% |
05-Apr-06 9:24 AM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 03-Apr-06 | Market Sale | 28,173 | $5.45 | $153,543.00 | (< 1%) 4.18M to 4.15M | 66% |
30-Mar-06 1:14 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 28-Mar-06 | Market Sale | 9,526 | $5.31 | $50,583.10 | (< 1%) 4.19M to 4.18M | 65% |
23-Mar-06 2:06 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 21-Mar-06 | Market Sale | 15,843 | $5.36 | $84,918.50 | (< 1%) 4.2M to 4.19M | 66% |
22-Mar-06 8:24 AM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 20-Mar-06 | Market Sale | 12,599 | $5.31 | $66,900.70 | (< 1%) 1.87M to 1.86M | 65% |
20-Mar-06 4:22 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 17-Mar-06 | Market Sale | 23,083 | $5.32 | $122,802.00 | (1%) 1.9M to 1.87M | 65% |
20-Mar-06 4:22 PM View: | Aventis Inc. | Introgen Therapeutics Inc. (INGN) | 16-Mar-06 | Market Sale | 82,434 | $5.44 | $448,441.00 | (4%) 1.98M to 1.9M | 66% |
11-Jan-06 1:41 PM View: | Albrecht James W Jr Chief Financial Officer | Introgen Therapeutics Inc. (INGN) | 10-Jan-06 | Option Exercise | 19,200 | $0.39 | $7,507.20 | 1200% 1.6K to 20.8K | |
04-Jan-06 3:27 PM View: | Parker David L Vice President | Introgen Therapeutics Inc. (INGN) | 30-Dec-05 | Option Exercise | 15,000 | $0.52 | $7,785.00 | 36% 41.81K to 56.81K | |
10-Nov-05 11:19 AM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 08-Nov-05 | Market Sale | 29,000 | $6.20 | $179,800.00 | (1%) 2.01M to 1.98M | 70% |
08-Nov-05 1:38 PM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 07-Nov-05 | Market Sale | 36,000 | $6.22 | $223,920.00 | (< 1%) 4.09M to 4.05M | 70% |
08-Nov-05 1:38 PM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 04-Nov-05 | Market Sale | 44,000 | $5.87 | $258,280.00 | (1%) 4.13M to 4.09M | 69% |
01-Nov-05 1:53 PM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 28-Oct-05 | Market Sale | 33,000 | $5.24 | $172,920.00 | (2%) 2.12M to 2.09M | 65% |
28-Oct-05 10:20 AM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 27-Oct-05 | Market Sale | 63,000 | $5.03 | $316,890.00 | (3%) 2.18M to 2.12M | 63% |
26-Oct-05 2:54 PM View: | Nance David G CEO & President Director 10% Owner | Introgen Therapeutics Inc. (INGN) | 26-Oct-05 | Grant | 56,090 | $0.00 | $56.09 | 3% 2.24M to 2.29M | |
20-Sep-05 2:25 PM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 16-Sep-05 | Market Sale | 10,392 | $5.52 | $57,363.80 | (< 1%) 2.19M to 2.18M | 67% |
14-Sep-05 3:49 PM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 13-Sep-05 | Market Sale | 28,272 | $5.75 | $162,564.00 | (1%) 2.22M to 2.19M | 68% |
13-Sep-05 3:56 PM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 12-Sep-05 | Market Sale | 33,200 | $5.81 | $192,892.00 | (1%) 2.26M to 2.22M | 68% |
12-Sep-05 3:49 PM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 08-Sep-05 | Market Sale | 25,000 | $5.75 | $143,750.00 | (1%) 2.28M to 2.26M | 68% |
09-Sep-05 10:55 AM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 07-Sep-05 | Market Sale | 40,253 | $5.82 | $234,272.00 | (2%) 2.32M to 2.28M | 68% |
08-Sep-05 1:38 PM View: | Aventis Inc | Introgen Therapeutics Inc. (INGN) | 06-Sep-05 | Market Sale | 165,260 | $5.97 | $986,602.00 | (7%) 2.49M to 2.32M | 69% |